News BioMarin Pharmaceutical Inc.

Equities

BMRN

US09061G1013

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-15 pm EDT			5-day change	1st Jan Change
91.51 ^USD	-0.77%		+4.85%	-5.09%

Apr. 01	Biomarin Pharmaceutical Insider Sold Shares Worth $2,173,341, According to a Recent SEC Filing	MT
Mar. 12	Transcript : BioMarin Pharmaceutical Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 01:35 PM

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BioMarin to Host First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, April 24, 2024, at 4:30pm ET	Apr. 10	PR
Biomarin Pharmaceutical Insider Sold Shares Worth $2,173,341, According to a Recent SEC Filing	Apr. 01	MT
New Data to be presented for BioMarin's VOXZOGO in Children with Hypochondroplasia and Achondroplasia at the American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting	Mar. 13	AQ
Transcript : BioMarin Pharmaceutical Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 01:35 PM	Mar. 12
BioMarin Pharmaceutical Says Voxzogo Leads to Height Gains in Children With Achondroplasia	Mar. 12	MT
Transcript : BioMarin Pharmaceutical Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-11-2024 10:40 AM	Mar. 11
Biomarin Pharmaceutical Insider Sold Shares Worth $348,280, According to a Recent SEC Filing	Mar. 07	MT
BioMarin Pharmaceutical Appoints Cristin Hubbard as Chief Commercial Officer	Mar. 07	MT
BioMarin Announces Appointment of Cristin Hubbard as Chief Commercial Officer	Mar. 07	PR
Biomarin Announces Board Changes, Effective May 20, 2024	Mar. 07	CI
Transcript : BioMarin Pharmaceutical Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 12:50 PM	Mar. 05
BioMarin Scheduled to Participate in March Investor Conferences	Mar. 04	AQ
BioMarin Scheduled to Participate in March Investor Conferences	Mar. 01	PR
BioMarin Pharmaceutical Gets DOJ Subpoena for Documents Related to Vimizim, Naglazyme -- Update	Feb. 26	DJ
BioMarin Pharma gets DOJ subpoena on sponsored testing programs for two therapies	Feb. 26	RE
BioMarin Pharmaceutical Gets DOJ Subpoena for Documents Related to Vimizim, Naglazyme	Feb. 26	DJ
BioMarin Pharma gets DOJ subpoena on certain drug testing programs	Feb. 26	RE
Wedbush Adjusts BioMarin Pharmaceutical's PT to $80 From $78, Keeps Neutral Rating; Continues to See Limited Upside	Feb. 23	MT
Transcript : BioMarin Pharmaceutical Inc., Q4 2023 Earnings Call, Feb 22, 2024	Feb. 22
BioMarin: Q4 Earnings Snapshot	Feb. 22	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News BioMarin Pharmaceutical Inc.

Equities

BMRN

US09061G1013

Summary

Filters